Drug prices in the US might overstate pharmaceuticals' long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.
OHE Lunchtime Seminar with Sir Geoffrey Owen and Professor Michael Hopkins. The biotech sector of the US has enjoyed a success that the UK sector has found difficult to match. Will the Brexit improve or damage UK's biotech sector prospects?
OHE’s Yan Feng and Grace Hampson, along with colleagues from the Health Foundation and RAND Europe, have published a new paper in Applied Economics and Finance which explores the factors that determine health care expenditure in OECD countries.
In this blog we (1) summarise the current status of the EQ-5D-5L value set for England; (2) highlight NICE’s recent statement on the values to be used in the reference case; (3) briefly explain why there are differences between the EQ-5D-3L and EQ-5D-5L; and (4) discuss why those differences might be important. We then (5) explain the next steps, including an independent quality assurance of the value set, and (6) provide an overview of current research projects underway at OHE to provide further evidence on the implications of new value sets for HTA and other uses.
